12 Month Price Forecast For MRK
Distance to MRK Price Forecasts
MRK Price Momentum
๐ค Considering Merck (MRK)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 11:16 AM UTC
MRK Analyst Ratings & Price Targets
Based on our analysis of 38 Wall Street analysts, MRK has a bullish consensus with a median price target of $114.00 (ranging from $95.00 to $148.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $86.40, the median forecast implies a 31.9% upside. This outlook is supported by 18 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Colin Bristow at UBS, projecting a 71.3% upside. Conversely, the most conservative target is provided by Chris Schott at JP Morgan, suggesting a 10.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRK Analyst Consensus
MRK Price Target Range
Latest MRK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRK.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 5, 2025 | Citigroup | Andrew Baum | Buy | Maintains | $115.00 |
Feb 5, 2025 | B of A Securities | Tim Anderson | Buy | Maintains | $112.00 |
Feb 5, 2025 | BMO Capital | Evan David Seigerman | Market Perform | Maintains | $96.00 |
Feb 5, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $106.00 |
Jan 28, 2025 | Citigroup | Andrew Baum | Buy | Maintains | $125.00 |
Jan 21, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $113.00 |
Jan 13, 2025 | Leerink Partners | Daina Graybosch | Outperform | Maintains | $119.00 |
Jan 8, 2025 | Truist Securities | Robyn Karnauskas | Hold | Downgrade | $110.00 |
Jan 8, 2025 | UBS | Colin Bristow | Buy | Maintains | $120.00 |
Dec 20, 2024 | BMO Capital | Evan David Seigerman | Market Perform | Downgrade | $105.00 |
Dec 10, 2024 | B of A Securities | Tim Anderson | Buy | Reinstates | $121.00 |
Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Peer Perform | Initiates | $0.00 |
Nov 7, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $130.00 |
Nov 6, 2024 | Guggenheim | Seamus Fernandez | Buy | Maintains | $130.00 |
Nov 1, 2024 | BMO Capital | Evan David Seigerman | Outperform | Maintains | $136.00 |
Nov 1, 2024 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $123.00 |
Nov 1, 2024 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $110.00 |
Oct 25, 2024 | Citigroup | Andrew Baum | Buy | Maintains | $130.00 |
Oct 17, 2024 | Bernstein | Market Perform | Initiates | $115.00 | |
Oct 9, 2024 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $132.00 |
Stocks Similar to Merck & Co Inc
The following stocks are similar to Merck based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Merck & Co Inc (MRK) Financial Data
Merck & Co Inc has a market capitalization of $219.17B with a P/E ratio of 12.9x. The company generates $63.17B in trailing twelve-month revenue with a 19.2% profit margin.
Revenue growth is +4.4% quarter-over-quarter, while maintaining an operating margin of +26.2% and return on equity of +28.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Merck & Co Inc (MRK) Company Overview
About Merck & Co Inc
Global healthcare company specializing in pharmaceuticals.
Merck & Co., Inc. generates revenue through two primary segments: Pharmaceuticals and Animal Health. The Pharmaceutical segment focuses on developing and selling a wide range of medications, including cancer treatments, vaccines, and therapies for various health conditions. The Animal Health segment offers veterinary pharmaceuticals and services, capitalizing on the growing demand for animal healthcare products.
Founded in 1891 and based in Rahway, New Jersey, the company engages in multiple collaborative agreements for drug development with partners like Daiichi Sankyo and AstraZeneca, enhancing its product pipeline. Merck's extensive portfolio includes well-known brands such as Keytruda and Gardasil, positioning it as a significant player in both human and animal health markets.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
70,000
CEO
Mr. Robert M. Davis J.D.
Country
United States
IPO Year
1970
Website
www.merck.comMerck & Co Inc (MRK) Latest News & Analysis
Verizon is the sole Dow Dog where dividends from a $1K investment exceed its share price, backed by strong free cash flow. Analysts forecast net gains of 15.23% to 33.94% by February 2026 for top Dow Dogs.
Verizon's strong dividend yield and free cash flow position it favorably among Dow Dogs, indicating potential for solid returns as analysts project significant gains by 2026.
Merck & Co. (NYSE:MRK) is a leading American pharmaceutical firm known for its brand-name drugs, including Keytruda, and extensive advertising on major TV networks.
Merck's strong brand recognition and successful drug portfolio, like Keytruda, indicate potential for revenue growth, impacting stock performance and investor confidence.
Should You Pick MRK Stock At $90?
6 days agoMerck (NYSE: MRK) Q4 results exceeded estimates, with revenue of $15.6 billion and adjusted earnings of $1.72 per share, surpassing expectations of $15.5 billion and $1.62.
Merck's Q4 results beat estimates, indicating strong performance and potential for growth, which could boost investor confidence and drive the stock price higher.
Levi & Korsinsky is investigating Merck & Co. (NYSE:MRK) for potential federal securities law violations following their Q4 and full-year 2024 results announcement on February 4, 2025.
Merck's potential securities violations may lead to legal repercussions and affect stock performance, impacting investor confidence and share value.
Levi & Korsinsky is investigating Merck & Co. (NYSE: MRK) for potential securities law violations following their Q4 and full-year 2024 results announcement on February 4, 2025.
Merck's investigation for potential federal securities law violations could impact its stock price and investor confidence, affecting trading strategies and portfolio valuations.
Merck (MRK) is being evaluated for its potential as a strong dividend stock, highlighting the challenges investors face in identifying quality dividend-paying companies.
Merck's potential as a dividend stock affects its attractiveness for income-focused investors, impacting stock demand and price stability.
Frequently Asked Questions About MRK Stock
What is Merck & Co Inc's (MRK) stock forecast for 2025?
Based on our analysis of 38 Wall Street analysts, Merck & Co Inc (MRK) has a median price target of $114.00. The highest price target is $148.00 and the lowest is $95.00.
Is MRK stock a good investment in 2025?
According to current analyst ratings, MRK has 18 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $86.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MRK stock?
Wall Street analysts predict MRK stock could reach $114.00 in the next 12 months. This represents a 31.9% increase from the current price of $86.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Merck & Co Inc's business model?
Merck & Co., Inc. generates revenue through two primary segments: Pharmaceuticals and Animal Health. The Pharmaceutical segment focuses on developing and selling a wide range of medications, including cancer treatments, vaccines, and therapies for various health conditions. The Animal Health segment offers veterinary pharmaceuticals and services, capitalizing on the growing demand for animal healthcare products.
What is the highest forecasted price for MRK Merck & Co Inc?
The highest price target for MRK is $148.00 from Colin Bristow at UBS, which represents a 71.3% increase from the current price of $86.40.
What is the lowest forecasted price for MRK Merck & Co Inc?
The lowest price target for MRK is $95.00 from Chris Schott at JP Morgan, which represents a 10.0% increase from the current price of $86.40.
What is the overall MRK consensus from analysts for Merck & Co Inc?
The overall analyst consensus for MRK is bullish. Out of 38 Wall Street analysts, 18 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $114.00.
How accurate are MRK stock price projections?
Stock price projections, including those for Merck & Co Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.